Titolo | Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and b-Myb via direct and indirect mechanisms |
---|---|
Tipo di pubblicazione | Articolo su Rivista peer-reviewed |
Anno di Pubblicazione | 2002 |
Autori | Tanno, Barbara, Negroni Anna, Vitali Roberta, Pirozzoli M.C., Cesi Vincenzo, Mancini C., Calabretta B., and Raschellà Giuseppe |
Rivista | Journal of Biological Chemistry |
Volume | 277 |
Paginazione | 23172-23180 |
ISSN | 00219258 |
Parole chiave | 2 morpholino 8 phenylchromone, Animals, article, Assays, Binding Sites, biochemistry, Cell Cycle Proteins, Cell Division, cell proliferation, Cells, controlled study, Cultured, Diseases, DNA responsive element, DNA-Binding Proteins, gene control, gene deletion, gene expression regulation, Genes, Genetic, human, human cell, Humans, Insulin, Insulin-Like Growth Factor Binding Protein 5, Insulin-Like Growth Factor II, Mice, Mutagenesis, mutant protein, myb, Neoplastic, Neuroblastoma, neuroblastoma cell, phosphatidylinositol 3 kinase, phosphatidylinositol 3 kinase inhibitor, priority journal, promoter region, Promoter Regions (Genetics), protein b myb, protein c Myb, protein expression, protein kinase B, Protein-Serine-Threonine Kinases, Proteins, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-akt, reporter gene, somatomedin binding protein 5, somatomedin C, somatomedin C receptor, Trans-Activation (Genetics), Trans-Activators, transactivation, Transcription, transcription regulation, Tumor Cells, Tumors, unclassified drug |
Abstract | Neuroblastoma (NB), a malignant childhood tumor deriving from the embryonic neural crest, is sensitive to the growth-stimulating effects of insulin-like growth factors (IGFs). Aggressive cases of this disease often acquire autocrine loops of IGF production, but the mechanisms through which the different components of the IGF axis are regulated in tumor cells remain unclear. Upon conditional expression of c-Myb in a NB cell line, we detected up-regulation of IGF1, IGF1 receptor, and insulin-like growth factor-binding protein 5 (IGFBP-5) expression. Analysis of the IGFBP-5 promoter revealed two potential Myb binding sites at position -59 to -54 (M1) and -429 to -424 (M2) from the transcription start site; both sites were bound by c-Myb and B-Myb in vitro and in vivo. Reporter assays carried out using the proximal region of the human IGFBP-5 promoter demonstrated that c-Myb and B-Myb enhanced transcription. However, site-directed mutagenesis and deletion of the Myb binding sites coupled with reporter assays revealed that M2 but not M1 was important for Myb-dependent transactivation of the IGFBP-5 promoter. The double mutant M1/M2 was still transactivated by c-Myb, suggesting the existence of Myb binding-independent mechanisms of IGFBP-5 promoter regulation. A constitutively active AKT transactivated the IGFBP-5 promoter, whereas the phosphatidylinositol 3-kinase inhibitor LY294002 suppressed it. Moreover, the kinase dead dominant negative K179M AKT mutant was able to inhibit transcription from the M2 and M1/M2 IGFBP-5 mutant promoters. Deletion analysis of the IGFBP-5 promoter revealed that the AKT-responsive region lies between nucleotides -334 and -83. Together, these data suggest that the Myb binding-independent transactivation of the IGFBP-5 promoter was due to the activation of the phosphatidylinositol 3-kinase/AKT pathway likely mediated by IGF1 receptor-dependent signals. Finally, IGFBP-5 was able to modulate proliferation of NB cells in a manner dependent on its concentration and on the presence of IGFs. |
Note | cited By 39 |
URL | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037189476&doi=10.1074%2fjbc.M200141200&partnerID=40&md5=7a6aa26be7134e975adf36fbaf436e2d |
DOI | 10.1074/jbc.M200141200 |
Citation Key | Tanno200223172 |